Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date.
At the company’s 2026 Commercial Day, Chairman and CEO
Angola’s business environment continues to create opportunities for entrepreneurs, established companies, and investors across a range of industries. As bu
XAUUSD: SELL 4341.46-4399.06, TP1-4283.86, TP2-4133.66.A month without swaps on majors! Learn moreLong-term trend: long. The maximum accumulation of volume
Prediction markets currently assign more than a 50% probability to the S&P 500 crossing 8,000 by year-end amid President Donald Trump’s optimism that the stock market is headed higher.
Albany International (NYSE:AIN) said it has completed its strategic review and will retain its Amelia Earhart Drive structures assembly facility in Salt Lake City after reaching an amended agreement with Sikorsky on the CH-53K program.
The company began exploring strategic alternatives for its stru
9:58 PM – I added another 1/3 position to my GLAD holding today as shares traded higher from the 10 DMA with an increase in volume. This is a very typical
Navigating the Brits BorderMoving to the United Kingdom is a dream shared by professionals, students, and families from all corners of the globe. The UK im
8:50 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch Listhttps://buyingbreakouts.com/wed-9-2-ndsn-lighte
8:55 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List.https://buyingbreakouts.com/wed-9-2-oke-traded
8:40 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List.https://buyingbreakouts.com/wed-9-2-eix-contin
Annovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements
8:45 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch Listhttps://buyingbreakouts.com/wed-9-2-ph-next-sup
8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List.https://buyingbreakouts.com/wed-9-2-oii-lighte
8:35 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List.https://buyingbreakouts.com/wed-9-2-md-a-fresh
Cryptocurrency asset management giant Grayscale noted on Wednesday, Sept. 2, that Bitcoin is gradually decoupling from technology stocks while its correlation with gold continues to rise.
